Physician profile
William A Lanting
NPI 1205866837
$35,900.48
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $2,055 · 2021: $8,272 · 2022: $4,182 · 2023: $3,842 · 2024: $1,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,462 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,071 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,461.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,071.00 |
| Education | $112.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $11,668.44 | 2019-2024 | Xolair |
| Genzyme Corporation | $5,659.15 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $3,856.03 | 2019-2024 | Fasenra, Tezspire, Breztri |
| Shire North American Group INC | $3,614.39 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $3,312.59 | 2019-2024 | Dupixent |
| Glaxosmithkline, LLC. | $1,257.43 | 2019-2024 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $1,141.84 | 2020-2024 | Hyqvia, Takhzyro, Eohilia |
| Biohaven Pharmaceuticals, INC. | $604.05 | 2020-2021 | |
| Csl Behring | $554.59 | 2019-2024 | Hizentra, Haegarda |
| Amgen INC. | $495.50 | 2021-2024 | Tezspire |
| Pfizer INC. | $491.63 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $476.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $389.71 | 2019-2024 | |
| Octapharma USA, INC. | $352.48 | 2019-2021 | |
| Abbvie INC. | $338.67 | 2021-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $306.56 | 2022 | |
| Biocryst US Sales Co., LLC | $267.29 | 2021-2023 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.96 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $148.54 | 2019-2020 | |
| Optinose US, INC. | $113.04 | 2019-2022 | |
| Kaleo, INC. | $101.40 | 2020-2024 | Auvi-Q |
| Alk-Abello, INC | $100.52 | 2019 | |
| Pharming Healthcare, INC. | $78.74 | 2020-2022 | |
| Greer Laboratories, INC. | $49.94 | 2019 | |
| Lilly USA, LLC | $48.83 | 2021-2024 | Ebglyss |
| Sanofi-Aventis U.S. LLC | $43.87 | 2020-2021 | |
| Allergan, INC. | $41.31 | 2020 | |
| Merck Sharp & Dohme LLC | $36.66 | 2021-2023 | |
| Biocryst Pharmaceuticals, INC. | $32.97 | 2020 | |
| Incyte Corporation | $31.09 | 2021-2022 | |
| Leo Pharma INC. | $26.86 | 2022 | |
| Uswm, LLC | $24.00 | 2021 | |
| Eyevance Pharmaceuticals LLC | $20.45 | 2019 | |
| Grifols USA, LLC | $15.07 | 2022 | |
| Mylan Specialty L.P. | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lanting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.